Therium Exceeds $1 Billion Milestone In Latest Fundraise From Global Institutional Investors

Jersey, Channel Islands, 25 March, 2019. Therium Group Holdings Limited, a leading global provider of litigation, arbitration and specialty legal finance, today announced that it has exceeded an important $1billion milestone of funds raised, following a latest fund raise of £325 million from three global institutional investors, including a sovereign wealth fund, to finance litigation and arbitration globally. It is Therium’s largest fund and follows the £200 million raised in February 2018.

John Byrne, Co-Founder and CEO of Therium Capital Management Limited, said: “We are thrilled to announce the closing of our latest fund, Therium’s largest to date. Raising over $1 billion is an important milestone for the industry and underscores Therium’s leading position in the litigation finance industry globally. Interest from high quality institutional investors was stronger than ever, driven by the rapid growth of the firm, the very strong outlook for our business globally and our track record. We are delighted to have the backing of world leading institutional investors in our new fund and we are very excited about the ongoing high growth opportunity ahead for Therium, which is now in its 11th year.”

Neil Purslow, Co-Founder and Chief Investment Officer of Therium Capital Management Limited, said: “The demand for our litigation and arbitration funding continues at pace across all of our jurisdictions. The benefits of funding are becoming increasingly widespread across the world; from claimants that would not otherwise have the capital to launch their claims, to the largest corporates that use funding to transform claims into financial assets. In line with this, we are seeing a steady rise of single case funding as well as litigation and arbitration financing across multiple dispute types.”

Therium recently announced the opening of an office in Australia, to serve Asia-Pacific, where the firm has been funding cases since 2011. The firm also has investment teams in the UK, USA, Germany, Spain and Norway. Therium was the first commercial litigation funder to have operations on the ground in Germany and Scandinavia and it was the first European firm to launch a full service business in the US.

Therium will use the new funds to continue to invest in litigation and arbitration cases globally across sectors including financial services, energy and mining, industrials, technology, media and entertainment, and across all forms of commercial litigation and arbitration. Therium invests in a broad range of complex commercial disputes, from securities and shareholder actions, international arbitration, competition and anti-trust cases, through to intellectual property, insolvency and group and class actions. Furthermore, demand for Therium’s specialty legal finance solutions from corporates and law firms continues apace across jurisdictions. The new fund is expected to be deployed within two years.

In November 2018, Therium won the ‘Insolvency Litigation Funder of the Year’ award at the Turnaround Restructuring and Insolvency awards in London in recognition of its cross border insolvency funding expertise and leading track record.

In Chambers and Partners’ inaugural litigation support directory 2018, Therium was ranked as a Tier 1 litigation funder, and Neil Purslow was named a leading individual in the litigation funding industry. Therium is a founder member of the Association of Litigation Funders of England and Wales.

Last month, Therium Capital Management was top ranked as one of the two “Leading” litigation and arbitration funding firms in the UK by legal and business directory Leaders League, in their 2019 ranking of litigation funding. Therium was also ranked as “Excellent” in the 2019 US ranking

Case highlights, which are in the public domain, include:

  • Sharp and others v Lloyds Banking Group (re Lloyds’s acquisition of HBOS)
  • Noel Edmonds v Lloyds Banking Group
  • Consumers v VW re Dieselgate
  • Road Haulage Association v Truck manufacturers
  • Richard Lloyd v Google Inc (re data protection)
  • UK retailers v Mastercard and Visa (re interchange fees)
  • PCP Capital Partners v Barclays Bank plc
  • Bates & Ors v Post Office Ltd
  • Atlant Entreprenor v City of Oslo
  • Webb v GetSwift Ltd
  • Shareholders v Commonwealth Bank of Australia Ltd

About Therium

Therium is a leading global provider of litigation, arbitration and specialty legal finance active in England and Wales and internationally since 2009.  Over that period, Therium has funded claims with a total value exceeding £34 billion including many of the largest and most high profile funded cases.  The firm has investment teams in the UK, USA, Australia, Spain, Germany and Oslo, supplementing its resources in its corporate headquarters in Jersey, Channel Islands.

Therium has established a track record of success in litigation finance in all forms including single case litigation and arbitration funding, funding law firms and funding portfolios of litigation and arbitration claims.  This track record enabled the firm to raise the then single largest investment into litigation finance of £200 million in 2015.  The latest raise builds upon the previous raise of £200m which closed in only February 2018.

Therium has raised over $1 billion since its foundation, which includes the latest £325 million fund raised in March 2019.

Therium has consistently been at the forefront of innovation in litigation finance, pioneering the combined use of insurance tools alongside funding vehicles, and introducing portfolio funding products into the UK.  The firm’s ability to develop innovative funding arrangements and bespoke financial solutions for litigants and law firms complements its unmatched experience and rigorous approach to funding a wide range of commercial disputes throughout the world.

www.therium.com

Announcements

View All

Legal Bay Presettlement Funding Reports Updates to Zantac Lawsuits

By Harry Moran |

Legal-Bay LLC, a leading pre settlement funding company, reports that November's $2.2 billion ruling against GlaxoSmithKline has still not been distributed to 80,000+ Zantac plaintiffs. The UK-based pharmaceutical company has been the target of numerous lawsuits for the past five years with plaintiffs alleging the popular heartburn medication causes cancer, and that the company failed to warn users that its main ingredient—ranitidine—may be a human carcinogen.

Testing last month determined how such dangerous levels of ranitidine ended up in the antacid product. As it turns out, impurities in the NDMA found in ranitidine increase when exposed to higher temps and humid conditions. Meaning that the Zantac may have been manufactured correctly, but when it was stored in a damp bathroom or glove compartment of a car, users themselves may have unwittingly triggered the very agent that caused their cancer. 

Chris Janish, CEO of Legal Bay, says, "GSK felt it was in the company's best interest to settle the lawsuits in order to appease shareholders rather than draw out litigation endlessly, especially considering they have been able to do so while providing no admission of liability. While we don't have an exact timeline for when payouts are expected to begin, we are nonetheless offering funding for Zantac plaintiffs while they wait."

To apply for a cash advance lawsuit loan from your anticipated GSK Zantac lawsuit settlement, please visit the company's website HERE or call 877.571.0405.   

There is no way to estimate final settlement amounts or how much each plaintiff's case will be worth. Similar case values have been determined based on extent/amount of injuries along with the level of merit to the case. Each case is unique, and many factors go into deciding final damages. For the Zantac lawsuit payouts, plaintiffs will fall into one of three tiers:

  • Tier I:

Tier 1 injuries can expect payouts in the $300,000 range.  Injuries in this tier include cancers of the stomach, prostate, pancreas, or breast.

  • Tier II:

Tier 2 injuries can expect payouts between $80,000 and 160,000 in most cases.  Injuries in this tier include cancers of the major organs like bladder, kidney, or liver.

  • Tier III:

Tier 3 injuries are looking at payouts anywhere between $20,000 and $60,000.  Injuries in this tier vary greatly, but to a lesser extent than Tier I or II.

The verdicts in these lawsuits are wildly inconsistent and entirely unpredictable, and Legal Bay says there are no guarantees of award amounts nor time frames for payouts just based on the sheer number of claims to process. Nevertheless, Legal-Bay is one of the few legal funding companies who are providing some financial relief to Zantac lawsuit plaintiffs and their families with risk-free, non-recourse cash advance settlement loans. They have been a leader in the mass tort and Qui Tam arena for over fifteen years and have vast experience within this space. These litigations are complex, and Legal Bay has the knowledge and understanding to help plaintiffs navigate the complicated waters of the legal system.

If you're a plaintiff in an active GSK Zantac lawsuit and need an immediate cash advance from your anticipated settlement, please visit the company's website HERE or call 877.571.0405 where agents are standing by to hear about your specific case. 

Legal-Bay is one of the best lawsuit loan companies when it comes to mass tort and Qui Tam litigations, and has a great reputation within the industry. Legal-Bay assists plaintiffs in all types of class action and mass tort lawsuits, including: Round Up, Hernia Mesh, IVC Filters, Essure, Exactech hip and knee recall, Sex Abuse cases, JUUL, and more.

Legal-Bay assists plaintiffs in all other types of lawsuits including personal injury, dog bites, motor vehicle accidents, medical malpractice, police brutality, unlawful incarceration, workplace discrimination, wrongful termination, and more.

Legal-Bay's loan for settlement funding programs are designed to provide immediate cash in advance of a plaintiff's anticipated monetary award. While it's common to refer to these legal funding requests as settlement loans, loans for settlements, law suit loans, loans for lawsuits, etc., the "lawsuit loan" funds are, in fact, non-recourse. That means there's no risk when it comes to loans in lawsuit settlements because there is no obligation to repay the money if the recipient loses their case. Therefore, terms like settlement loan, loans for lawsuit, loans on settlement, or lawsuit loan funds don't necessarily apply, as the "loan on lawsuit" isn't really a loan at all, but rather a stress-free cash advance.

Legal-Bay is known to many as the best lawsuit funding provider in the industry for their helpful and knowledgeable staff, low rates, and quick turnaround, sometimes within 24-48 hours once all documents have been received.

To apply right now for a loan settlement program, please visit the company's website HERE or call toll-free at: 877.571.0405 where agents are standing by to answer any questions.

Latest Burford Quarterly Explores Key Trends Driving Innovation in Commercial Disputes in 2025

By Harry Moran |

Burford Capital, the leading global finance and asset management firm focused on law, today releases its latest Burford Quarterly, a journal of legal finance that explores top trends at the nexus of law and finance.

This Burford Quarterly examines the innovative ways in which businesses and law firms are reimagining their financial strategies around commercial disputes. Examples of this include law firms using creative billing structures as alternatives to hourly fees; companies choosing to opt out of litigation to maximize and accelerate recoveries; or businesses monetizing IP assets, allowing for continued investment in other vital areas of the business.

Articles in the Burford Quarterly No.1 2025 include:

  • The innovation engine: Legal finance for forward-thinking law firms

As law firms launch into 2025, a year that promises continued disruption and opportunity, innovation is not a choice—it's an imperative. Forward-thinking firms are reimagining their financial strategies, moving beyond traditional models to embrace legal finance as a critical tool for transformation. In this article, Travis Lenkner and Emily Slater explore innovative ways legal finance is helping firms solve pressing challenges and accelerate growth. 

  • Healthcare antitrust opt-outs: Improving liquidity by monetizing valuable legal claims

An increasing number of healthcare businesses are recognizing the value that legal finance provides in helping to mitigate the financial strain of high-cost litigation and expedite recoveries in high-stakes litigation. Ahead of a March 2025 opt-out deadline for claimants in the Blue Cross Blue Shield (BCBS) antitrust class actions, Charles Griffin summarizes insights from a recent webcast in which experts from Burford and Paul Hastings presented factors hospital networks and providers should consider in weighing their options.

  • Legal finance and life sciences: Unlocking IP potential in pharma, biotech and medical devices

Innovation in Europe's life sciences and pharmaceutical sectors is vital, but long R&D cycles and short profit windows pose challenges. Joshua Harris explains how legal finance helps companies protect and monetize IP assets, enabling continued investment in life-saving technologies.

  • International arbitration in London: Next-Gen leaders' perspective

Geoff Nicholas, Christiane Deniger and James MacKinnon lead a Burford roundtable with London-based arbitration lawyers. Partners from A&O Shearman, Debevoise & Plimpton, Bryan Cave Leighton Paisner and Freshfields share their insights on key trends and challenges shaping international arbitration, including the use of technology and AI and arbitral efficiency.

Aviva Will, President of Burford Capital, says: "While the legal industry may be slow to evolve, legal finance is a powerful tool to drive innovation in the business of law. This issue of the Burford Quarterly highlights key trends in commercial litigation and arbitration in 2025 and shows how litigation funding continues to shape the legal industry. By providing capital and mitigating risk, funding removes barriers for businesses and facilitates growth, and the latest Quarterly brings insights, analysis and real-world examples of tools to help business executives, GCs, CLOs and law firm attorneys recognize and harness the full potential of finance for law."

About Burford Capital

Burford Capital is the leading global finance and asset management firm focused on law. Its businesses include litigation finance and risk management, asset recovery and a wide range of legal finance and advisory activities. Burford is publicly traded on the New York Stock Exchange (NYSE: BUR) and the London Stock Exchange (LSE: BUR), and it works with companies and law firms around the world from its offices in New York, London, Chicago, Washington, DC, Singapore, Dubai and Hong Kong.

For more information, please visit www.burfordcapital.com.

This announcement does not constitute an offer to sell or the solicitation of an offer to buy any ordinary shares or other securities of Burford.

Rockpoint Legal Funding Highlights TrialBase’s Deposition Services as a Game-Changer for Legal Professionals

By Harry Moran |

Rockpoint Legal Funding is excited to introduce their integration with TrialBase (TrialBase.com), a leader in certified deposition services and legal reporting solutions, as a valuable resource for legal professionals. Attorneys can now instantly apply for litigation funding from Rockpoint directly within Trialbase in order to cover deposition costs on their cases.

TrialBase's cutting-edge deposition management services are uniquely positioned to enhance the efficiency of legal teams, while Rockpoint Legal Funding continues to provide trusted non-recourse funding solutions that empower attorneys to focus on winning cases.

Why TrialBase is an Ideal Resource for Legal Professionals:

Legal professionals often face complex challenges, from managing intricate discovery processes to ensuring financial stability for their clients. Together, TrialBase and Rockpoint Legal Funding can address these issues through:

1.    Streamlined Deposition Services:

TrialBase offers certified deposition management solutions through an integrated platform, helping legal teams save time and enhance case preparation.

2.    Financial Stability for Clients:

Attorneys can use Rockpoint's litigation funding to cover deposition costs and to reduce financial stress - allowing attorneys to focus on their case strategies without unnecessary delays.

3.    Secure Digital Workflow:

Both companies leverage secure, user-friendly platforms, enabling seamless, efficient support for legal professionals.